Navigation Links
Isis Pharmaceuticals' Stanley Crooke Awarded Corporate Forum's Director of the Year
Date:9/18/2013

or who has positively contributed to taking the company through changes, including transitions that significantly increased value of the company.  During the last year, Isis has experienced substantial growth in all areas of its business, including the approval of KYNAMRO, advancement of its product pipeline with positive clinical data in multiple programs, and completion of several successful partnerships that should accelerate discovery and development of drugs to improve the lives of patients and significantly improve the Company's already strong financial position.   More information on the award, the 2013 honorees and the Corporate Directors Forum is available at www.directorsforum.com.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 30 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis Pharmaceuticals' business, the therapeutic and commercial potential of Isis' technologies and products in development, Isis' financial position and the commercial potential of KYNAMRO.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and sh
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovio Pharmaceuticals to Present at Investor Conferences and Town Hall Los Angeles
2. Actinium Pharmaceuticals Appoints Corey Sohmer As Vice President Of Finance And Business Development
3. GW Pharmaceuticals Commences Phase 1 Clinical Trial of GWP42006 as a Potential Treatment for Epilepsy
4. Teva Pharmaceuticals Donates to the National Multiple Sclerosis Society in recognition of Jack Osbourne as He Competes on "Dancing with the Stars"
5. JHP Pharmaceuticals Enters Agreement to Produce Unique Late Stage Ophthalmic Product
6. Actinium Pharmaceuticals Appoints Kaushik J. Dave, Ph.D., MBA As President, Chief Executive Officer And Director
7. Frost & Sullivan Lauds Adcock Ingrams Capability to Innovatively Cater to the Dynamic Needs of Emerging Pharmaceuticals Markets
8. Dr. David Hangauer, Chief Scientific Officer and Co-Founder, commits his career to Kinex Pharmaceuticals
9. Access Pharmaceuticals Awarded Second European Patent for MuGard
10. Cardioxyl Pharmaceuticals Appoints Shi Yin Foo, M.D., Ph.D., As Chief Medical Officer
11. Caldera Pharmaceuticals Announces Closing of Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Cardiologists at Henry Ford Hospital have implanted a device that ... heartbeat. With only handful of hospitals in the ... to add another option to its arsenal of tools for ... to pump. "This is a first in ... at a non-clinical trial site," says cardiologist Claudio Schuger ...
(Date:4/21/2015)... 21, 2015  St. Vincent Healthcare is raising ... Already following strict disinfection routines, St. Vincent Healthcare is ... eliminate harmful germs, like Ebola, methicillin-resistant Staphylococcus ... can infect patients during their hospital stay. ... Logo - http://photos.prnewswire.com/prnh/20150420/199749LOGO ...
(Date:4/21/2015)... smokers, was selected to present as a finalist at the American Heart Association,s Health Sciences Innovation ... Photo - http://photos.prnewswire.com/prnh/20150421/199989 ... ... ... of all cardiovascular disease is caused by smoking. The IntelliQuit™ device and mobile app ecosystem is ...
Breaking Medicine Technology:Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 2Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 3St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 2St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 3IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 2IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 3
... 11, 2011 Conatus Pharmaceuticals Inc. today announced the ... private placement financing.  This financing was led by new ... participation by existing investors; Aberdare Ventures, Advent Venture Partners, ... Fund.  Conatus will use the proceeds to advance the ...
... 2011 Stryker Corporation,s (NYSE: SYK ) ... 510(k) clearance for its MDM X3 Modular Dual Mobility ... to the company,s portfolio of next-generation technologies designed to ... and address a broader patient population, including both primary ...
Cached Medicine Technology:Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing 2Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System 2Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System 3
(Date:4/21/2015)... (PRWEB) April 21, 2015 Displays & ... force in the trade show exhibit building industry, announced ... the sales offices of Absolute Exhibits in Tustin, California.“It ... local shoppers to observe the variation in quality as ... & Exhibits,” explained Zenos Adduru. Mr. Adduru is the ...
(Date:4/21/2015)... Massachusetts (PRWEB) April 21, 2015 Henry ... uses Summit Care Exchange to automatically send ... that it needed to further improve communication with clinics ... Summit Provider Alert solution. , “Provider ... to retrieve the patient information they need to provide ...
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 22, 2015 ... Pipeline Review, H1 2015” provides comparative analysis ... The report strengthens R&D pipelines by identifying ... and best-in-class products. Complete report with TOC ... , The report also reviews key players ...
(Date:4/21/2015)... Texas (PRWEB) April 21, 2015 ... H1 2015” provides comparative analysis on the ... R&D pipelines by identifying new targets and ... Complete report with TOC is available @ ... also reviews key players involved in the ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Information is the ... Kevin Ryan, MD, FACP, empowers patients and their families with ... is the Rumor and Cancer is the Answer" and ... and informative language to guide patients from diagnosis through treatment ... patients active participants in their treatment, at home and in ...
Breaking Medicine News(10 mins):Health News:Displays & Exhibits Reveals Tustin, California Showroom Under New Management 2Health News:Henry Mayo Newhall Hospital to Improve Ambulatory Information Sharing with Summit Healthcare's Summit Provider Alert 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2
... in Spanish . , Researchers of the ... University of Granada (Spain) have discovered that extra virgin ... a paper published in the last issue of the renowned ... the bioactivity of polyphenols (this is, natural antioxidants) present in ...
... Patient Care launches fourth-year program that focuses on ... Feb. 5 /PRNewswire/ -- The Partnership ... effort led by southeastern Pennsylvania hospitals and one ... Blue Cross, announces its new initiatives for 2009-2011 ...
... It,s In Our Hands - Has Been Designed ... and Caregivers to Healthcare Resources and Services in ... the initiation of its Community Health Partnership (CHP), ... Bronx area, seeking to link Hispanic residents with ...
... /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin Board: ... developer, manufacturer and distributor in the People,s ... controlled subsidiary Beijing,Liang Fang Pharmaceutical Co., Ltd. ... million) in December 2008 for land use ...
... MinuteClinic, the pioneer and largest provider of ... that it has become a participating provider in ... South Carolina.BlueCross, Preferred Blue and Medicare Advantage members ... centers located in the Columbia and Greenville markets. ...
... 5 Palomar Medical Technologies, Inc. (Nasdaq: ... systems for cosmetic treatments, today announced financial results for ... Revenues for the quarter ended December 31, 2008 ... revenues, $2.2 million were royalty revenues, $0.5 million were ...
Cached Medicine News:Health News:Spanish scientists confirm extra virgin olive oil helps to combat breast cancer 2Health News:Region's Hospitals Engage in New Patient-Safety Efforts to Further Reduce Infections, Errors, and Improve Quality of Care 2Health News:Region's Hospitals Engage in New Patient-Safety Efforts to Further Reduce Infections, Errors, and Improve Quality of Care 3Health News:Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care 2Health News:Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care 3Health News:Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs 2Health News:Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs 3Health News:Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs 4Health News:Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs 5Health News:MinuteClinic Becomes Participating Provider With Preferred Blue Network of BlueCross BlueShield of South Carolina 2Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 2Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 3Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 4Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 5Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 6Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 7Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 8Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 9Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 10
Lyphochek Hemostasis Control is a multi-analyte control to help monitor coagulation factor assays and selected thrombosis risk assays. Assayed values are available for most major instrumentation....
... Liquichek Qualitative Urine Toxicology Control is a ... rapid urine drug screen panels, including Point ... test kits like Bio-Rad TOX/See, Biosite Triage ... qualitative results (+/) for popular kits and ...
Liquichek Reticulocyte Control is a human whole blood based control designed to monitor manual and automated methods for counting reticulocytes. Assayed values are provided at three clinically signif...
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
Medicine Products: